Administration

• Give with or without food.• For children who can't swallow tablets or children for whom calculated dosage doesn't correspond to available tablet strength, use a suspension but be aware that exposure to the suspension is 1.6 times greater than the tablet.• To prepare 160 ml of a 4-mg/ml suspension, add 80 ml of Ora-Plus to bottle containing eight valsartan 80-mg tablets and shake for at least 2 minutes. Allow suspension to stand for at least 1 hour. Then shake for at least 1 additional minute. Add 80 ml of Ora-Sweet to bottle and shake for at least 10 seconds before giving appropriate dose. May store suspension for 30 days at room temperature or up to 75 days if refrigerated.

Be aware that drug isn't recommended for children with glomerular filtration rate of less than 30 ml/minute/1.732.

Patient monitoring

• Monitor blood pressure closely, especially during initial therapy and dosage adjustments.• Assess potassium level. Stay alert for hyperkalemia.• Be aware that in black patients, drug may be ineffective when used alone. Additional agents may be required.

Patient teaching

• Tell patient he may take with or without food.• For children who can't swallow tablets or children for whom calculated dosage doesn't correspond to available tablet strength, show caregiver how to prepare a suspension.

In brief, 1101 patients with ACS, without left ventricular systolic dysfunction or clinical heart failure but increased concentration of a natriuretic peptide measured within 3-10 days after their qualifying event [[greater than or equal to] 80 ng/L for B-type NP (BNP) or [greater than or equal to] 400 ng/L for N-terminal pro-B-type NP (NT-proBNP)], were randomized to aliskiren, valsartan, their combination, or placebo (see Supplemental Fig.

Wael Al Mahmeed, Consultant Cardiologist and President of Emirates Cardiac Society said: "In a worldwide medical study conducted on 4,395 patients with Heart Failure and high blood pressure, Valsartan showed a reduction in combined morbidity and mortality for these patients, as well as decreased levels of atrial fibrillation (AF) by 37%, compared to another group which was not given the drug.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.